<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616404</url>
  </required_header>
  <id_info>
    <org_study_id>9321/14122018</org_study_id>
    <nct_id>NCT04616404</nct_id>
  </id_info>
  <brief_title>The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects With Newly Detected Impaired Fasting Glycaemia.</brief_title>
  <official_title>The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I Subjects With Newly Detected Impaired Fasting Glycaemia: a Double-blind, Placebo-controlled, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda di Servizi alla Persona di Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indena S.p.A</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda di Servizi alla Persona di Pavia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impaired fasting glucose (IFG) is a condition that precedes diabetes and increases the risk&#xD;
      of developing it. Studies support the hypoglycemic effect of Cynara cardunculus (Cs) extracts&#xD;
      due to the content of chlorogenic acid, which is a potent inhibitor of glucose 6-phosphate&#xD;
      translocase and of dicaffeoylquinic acid derivatives that modulate the activity of&#xD;
      alpha-glucosidase. Given this background, we investigated whether a new highly standardized&#xD;
      Cs extract could improve glycaemic control, insulin sensitivity and other metabolic&#xD;
      parameters (total, HDL and LDL cholesterol, Triglycerides, ApoB, ApoA, waist circumference,&#xD;
      Visceral adipose tissue by DXA) in overweight subjects with newly diagnosed IFG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes on glycemia</measure>
    <time_frame>Day 0, after 1 month and after 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on total cholesterol (mg/dl), HDL (mg/dl), total cholesterol/HLD, LDL (mg/dl), LDL/HDL, triglycerides (mg/dl), ApoA (mg/dl), ApoB (mg/dl), ApoB/ApoA, creatinine (mg/dl)</measure>
    <time_frame>Day 0, after 1 month and after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on AST (UI/l), ALT (UI/l), GGT (U/l)</measure>
    <time_frame>Day 0, after 1 month and after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on insulin (mcU/ml) and HOMA index</measure>
    <time_frame>Day 0, after 1 month and after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on glycated hemoglobin (%)</measure>
    <time_frame>Day 0, after 1 month and after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on A1c-Derived Average Glucose (mmol/l)</measure>
    <time_frame>Day 0, after 1 month and after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on maximum blood pressure (mmHg), minimum blood pressure (mmHg)</measure>
    <time_frame>Day 0, after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on waist circumference (cm)</measure>
    <time_frame>Day 0, after 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on VAT (g), lean and fat mass (g)</measure>
    <time_frame>Day 0, after 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Insulin Sensitivity</condition>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>500 mg of artichoke extract</intervention_name>
    <description>Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets with no active ingredient</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  without history of cardiovascular disease (CVD),&#xD;
&#xD;
          -  not taking any medication likely to affect glucose or lipid metabolism (oral&#xD;
             hypoglycemic agents and statins)&#xD;
&#xD;
          -  free of overt liver, renal and thyroid disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  drinking more than two standard alcoholic beverages/day (20 g of alcohol/day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda di Servizi alla Persona ''Istituto Santa Margherita''</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>impaired fasting glucose</keyword>
  <keyword>Cynara cardunculus</keyword>
  <keyword>Insulin Sensitivity</keyword>
  <keyword>Obesity</keyword>
  <keyword>Overweight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

